Stock BDTX BLACK DIAMOND THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Black Diamond Therapeutics, Inc. OTC Markets

Equities

BDTX

US09203E1055

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for Black Diamond Therapeutics, Inc. -.--% -.--%
16/05 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
09/05 Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Evolution of the average Target Price on Black Diamond Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9a68bb11e94af94b2704c8705fe8cc2.Xru1QkfuK3WzaV7pRNZfK2MpAwlpJa9ntOWsBWB7teo.KYv2DDO7Wx_dDAaAIpNmTQtQUnEBFOE3_rTqZFAOhb5t9-MIN4xNMfcIag~d7ab3524fcef7c5f5a49b01cf52fbf51

Analyst Recommendations on Black Diamond Therapeutics, Inc.

HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT
Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
BLACK DIAMOND THERAPEUTICS : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
BLACK DIAMOND THERAPEUTICS : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
BLACK DIAMOND THERAPEUTICS : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
BLACK DIAMOND THERAPEUTICS : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
BLACK DIAMOND THERAPEUTICS : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
BLACK DIAMOND THERAPEUTICS : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
BLACK DIAMOND THERAPEUTICS : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.04 USD
Average target price
12.6 USD
Spread / Average Target
+150.00%
High Price Target
16 USD
Spread / Highest target
+217.46%
Low Price Target
9 USD
Spread / Lowest Target
+78.57%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Black Diamond Therapeutics, Inc.

HC Wainwright
Wedbush
Piper Sandler
Stifel Nicolaus
Berenberg Bank

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BDTX Stock
  4. BDTX Stock
  5. Consensus Black Diamond Therapeutics, Inc.